ARNI (Arno Therapeutics) Total Stockholders Equity: $-5.71 Mil (As of Sep. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Arno Therapeutics Total Stockholders Equity?

Arno Therapeutics ARNI +1.00% Total Stockholders Equity is $-5.71 Mil as of Sep. 2016.

Arno Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2016 was $-5.71 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Arno Therapeutics's Book Value per Share for the quarter that ended in Sep. 2016 was $-0.12. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arno Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2016 was -0.00.

Arno Therapeutics  (OTCPK:ARNI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Arno Therapeutics's Book Value per Share for the quarter that ended in Sep. 2016 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.714244-0)/47.849
=-0.12

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Arno Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2016 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.004306 + 0.000782) / -5.714244
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arno Therapeutics Total Stockholders Equity Related Terms

Arno Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Arno Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arno Therapeutics Total Stockholders Equity Chart

Arno Therapeutics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 -12.27 -12.88 -0.59 -8.62

Arno Therapeutics Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.24 -8.62 -4.02 -5.22 -5.71
What does a Total Stockholders Equity of $-5.71 Mil mean?
Arno Therapeutics (ARNI) has a Total Stockholders Equity of $-5.71 Mil as of Sep. 2016. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Arno Therapeutics and its competitors.
Is Arno Therapeutics' Total Stockholders Equity too high?
Arno Therapeutics' current Total Stockholders Equity is $-5.71 Mil.
How does Arno Therapeutics' Total Stockholders Equity compare to PLPL and BTHE?
Arno Therapeutics' Total Stockholders Equity of $-5.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Arno Therapeutics and its competitors. Arno Therapeutics's current Total Stockholders Equity is $-5.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arno Therapeutics stock overvalued right now?
Arno Therapeutics (ARNI) has a current Total Stockholders Equity of $-5.71 Mil. The current Total Stockholders Equity is $-5.71 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Arno Therapeutics (ARNI), the current Total Stockholders Equity is $-5.71 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arno Therapeutics Business Description

Address 200 Route 31 North, Suite 104, Flemington, NJ, USA, 08822
Arno Therapeutics Inc operates as a biopharmaceutical company. It develops drug candidates to treat patients with cancer and other life-threatening diseases. It develops pre-clinical and clinical-stage product under the following name: Onapristone, AR-42, and AR-12. Onapristone is indicated for endometrial, prostate and breast cancer indications, AR-42 is provided for hematological malignancies and solid tumors indications and AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.